Age‐related phenotypes in breast cancer: A population‐based study

Amalie A. Svanøe,Rasmus O. C. Humlevik,Gøril Knutsvik,Anna K. M. Sæle,Cecilie Askeland,Lise M. Ingebriktsen,Ulrikke Hugaas,Amalie B. Kvamme,Amalie F. Tegnander,Kristi Krüger,Benedicte Davidsen,Erling A. Hoivik,Turid Aas,Ingunn M. Stefansson,Lars A. Akslen,Elisabeth Wik
DOI: https://doi.org/10.1002/ijc.34863
2024-02-08
International Journal of Cancer
Abstract:What's new? Breast cancers that develop prior to age 40 typically are aggressive and associated with poor prognosis. Whether age‐related factors influence the frequency of aggressive clinico‐pathologic features in breast cancer, however, remains unknown. In this population‐based study, the authors investigated age‐related tumor biology in breast cancer, particularly the role of tumor proliferation. Aggressive tumor features, including increased proliferation determined by Ki67 staining, were more frequent among patients under age 50, relative to older patients. Prognostic Ki67 values were also weaker among younger patients. The findings suggest that younger breast cancer patients have unique biological characteristics related to tumor aggressiveness. Breast cancer in young (<40 years) is associated with a higher frequency of aggressive tumor types and poor prognosis. It remains unclear if there is an underlying age‐related biology that contributes to the unfavorable outcome. We aim to investigate the relationship between age and breast cancer biology, with emphasis on proliferation. Clinico‐pathologic information, immunohistochemical markers and follow‐up data were obtained for all patients aged <50 (Bergen cohort‐1; n = 355, not part of a breast screening program) and compared to previously obtained information on patients aged 50 to 69 years (Bergen cohort‐2; n = 540), who participated in the Norwegian Breast Cancer Screening Program. Young breast cancer patients presented more aggressive tumor features such as hormone receptor negativity, HER2 positivity, lymph‐node metastasis, the HER2‐enriched and triple‐negative subtypes and shorter survival. Age <40 was significantly associated with higher proliferation (by Ki67). Ki67 showed weaker prognostic value in young patients. We point to aggressive phenotypes and increased tumor cell proliferation in breast cancer of the young. Hence, tumors of young breast cancer patients may present unique biological features, also when accounting for screen/interval differences, that may open for new clinical opportunities, stratifying treatment by age.
oncology
What problem does this paper attempt to address?